

APPLICANT FACSIMILE OF FORM PTO-1449 REV-7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CCI-007USDV	SERIAL NO. 10/646267
O 12 LIST OF PUBLICATIONS CITED BY APPLICANT (use several sheets if necessary)		APPLICANT Ball, Kathryn Lindsay et al.	
MAR 16 2004		FILING DATE August 22, 2003	GROUP 1654

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
X	A1 5,807,692	9/98	Kinzler et al.	437	7.21	
X	A2 5,672,508	9/97	Gyuris et al.	435	320.1	
X	A3 5,596,079	1/97	Smith et al.	530	328	
X	A4 5,424,400	6/95	Smith et al.	530	350	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
X	A5 FR 2,662,698	12/91	France			Abstr. <input checked="" type="checkbox"/>
X	A6 WO 96/35715	11/96	PCT			
X	A7 WO 97/42222	11/97	PCT			
X	A8 WO 97/03681	2/97	PCT			
X	A9 WO 96/14334	5/96	PCT			
X	A10 WO 95/06445	3/95	PCT			
X	A11 WO 95/13575	5/95	PCT			
X	A12 WO 95/31995	11/95	PCT			
X	A13 WO 94/09135	4/94	PCT			
X	A14 WO 94/02167	2/94	PCT			
X	A15 WO 93/12251	6/93	PCT			
X	A16 0 002 805	12/78	Europe			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

X	Adams, Peter D. et al. "Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors" <i>Molecular and Cellular Biology</i> 16:6623-6633 (Dec 1996).
X	Ball, Kathryn L. et al. (1996) "Cell-Cycle Arrest And Inhibition Of Cdk4 Activity By Small Peptides Based On The Carboxy-Terminal Domain Of p21 ^{WAF1} " <i>Current Biology</i> , Vol. 7 pp. 71-80;
X	Ball, Kathryn L. et al. (1996) "Human And Plant proliferating-Cell Nuclear Antigen Have A highly Conserved Binding Site For The p53-Inducible Gene product p21 ^{WAF1} " <i>Eur. J. Biochem.</i> Vol. 237 pp. 854-861;
X	Chen, Junjie et al. (1996) "p21 ^{Cip1/Waf1} Disrupts The Recruitment Of Human Fen1 By Proliferating-Cell Nuclear Antigen Into The DNA Replication Complex" <i>Proc. Natl. Acad. Sci. USA</i> , Vol 93, pp. 11597-11602;
Examiner	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CCI-007USDV	SERIAL NO. 10/646267
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ball, Kathryn Lindsay et al.	
		FILING DATE August 22, 2003	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>DL</i>	B1	Chen, Junjie et al. (1996) "Cyclin-Binding Motifs Are Essential For The Function of p21 ^{Cip1} " Molecular and Cellular Biology, Vol. 16, No. 9 pp. 4673-4682;
<i>X</i>	B2	Chen, Junjie et al. (1995) "Separate Domains Of p21 Involved In The Inhibition Of Cdk Kinase And PCNA", Nature, Vol. 374, pp. 386-388;
<i>DL</i>	B3	Chen, I-Tsuen et al. (1996) "Characterization of p21 ^{Cip1/Waf1} Peptide Domains Required For Cyclin E/Cdk2 and PCNA Interaction" Oncogene Vol. 12 pp. 595-607;
<i>X</i>	B4	Deng, Chuxia et al. (1995) "Mice Lacking p21 ^{Cip1/Waf1} Undergo Normal Development, But Are Defective In G1 Checkpoint Control", Cell, Vol. 82, pp. 675-684;
<i>X</i>	B5	Eastham, James A. et al. (1995) "In Vivo Gene Therapy with p53 or p21 Adenovirus For Prostate Cancer" Cancer Research, Vol. 55, pp. 5151-5155;
<i>X</i>	B6	El-Deiry, Wafik S. et al. (1993) "WAF1, A Potential Mediator Of p53 Tumor Suppression" Cell, Vol. 75, pp. 817-825;
<i>DL</i>	B7	Goubin, Francoise et al. (1995) "Identification of Binding Domains on the p21 ^{Cip1} Cyclin-Dependent Kinase Inhibitor" Oncogene, Vol. 10, pp. 2281-2287;
<i>X</i>	B8	Gu, Yong et al. (1993) "Inhibition Of CDK2 Activity In Vitro By An Associated-20 K Regulatory Subunit" Nature, Vol. 366, pp. 707-710;
<i>DL</i>	B9	Harper, J. Wade et al. (1995) "Inhibition Of Cyclin-Dependent Kinases By p21", Molecular Biology of the Cell, Vol. 6, pp. 387-400;
<i>X</i>	B10	Harper, J. Wade et al. (1993) "The p21 Cdk-Interacting Protein Cip1 Is A Potent Inhibitor Of G1 Cyclin-Dependent Kinases", Cell, Vol. 75, pp. 805-816;
<i>X</i>	B11	Hirakawa, Lea R. et al. (1995) "Sequence Of Human FEN-1, A Structure-Specific Endonuclease, And Chromosomal Localization Of The Gene (FEN1) In Mouse And Human" Genomics Vol. 25, pp. 220-225;
<i>DL</i>	B12	Lin, Jiayuh et al. (1996) "Analysis of Wild-Type and Mutant p21 ^{WAF-1} Gene Activities" Molecular and Cellular Biology, Vol. 16, No. 4, pp. 1786-1793;
<i>DL</i>	B13	Luo, Yan et al. (1995) "Cell-cycle Inhibition by Independent CDK and PCNA Binding domains In p21 ^{Cip1} " Nature Vol. 375, pp. 159-161;
<i>DL</i>	B14	MacLachlan, Timothy K. (1995) "Cyclins, Cyclin-Dependent Kinases And Cdk Inhibitors: Implications In Cell Cycle Control And Cancer" Critical Reviews in Eukaryotic Gene Expression, Vol. 5, No. 2, pp. 127-156;

Examiner

David L. L. Chen

Date Considered

11-17-06

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CCI-007USDV	SERIAL NO. 10/646267
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ball, Kathryn Lindsay et al.	
		FILING DATE August 22, 2003	GROUP 1646 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

X	C1	Nakanishi, Makoto et al. (1995) "The C-Terminal Region Of p21 ^{SD11/WAF1/CIP1} Is Involved In Proliferating Cell Nuclear Antigen Binding But Does Not Appear To Be Required For Growth Inhibition" The Journal of biological Chemistry, Vol. 270, No. 29, pp. 17060-17063;
X	C2	Nakanishi, Makoto et al. (1995) "Identification Of The Active Region Of The DNA Synthesis Inhibitory Gene p21 ^{SD11/CIP1/WAF1} " The EMBO Journal, Vol. 14, No. 3, pp. 555-563;
X	C3	Flores-Rozas, Hernan et al. (1994) "Cdk-Interacting Protein 1 Directly Binds With Proliferating Cell Nuclear Antigen And Inhibits DNA Replication Catalyzed By The DNA Polymerase δ Holozyme" Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 8655-8659
X	C4	Su, Jin-Yuan et al. (1995) "Cloning And Characterizatin Of The Xehepus Cyclin-Dependent Kinase Inhibitor p27 ^{XIC1} " Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 10187-10191;
X	C5	Voet et al. (1990) Biochemistry, John Wiley & Sons, Inc. pp 126-128, 228-234
X	C6	Waga, Shou et al. (1994) "The p21 Inhibitor Of Cyclin-Dependent Kinases Controls DNA Replication By Interaction With PCNA" Nature Vol. 369, pp. 574-578
X	C7	Waldman, Todd et al. (1995) "p21 Is necessary For The p53-Mediated G ₁ Arrest In Human Cance Cells" Cancer Research, Vol. 55, pp. 5187-5190;
X	C8	Warbrick, Emma et al. (1995) "A Small Peptide Inhibitor Of DNA Replication Defines The Site Of Interaction Between The Cyclin-Dependent Kinase Inhibitor p21 ^{WAF1} And proliferating Cell Nuclear Antigen" Current Biology, Vol. 5 No. 3, pp. 275-282;
X	C9	Warbrick, Emma et al. (1997) "Homologous Regions of Fen1 and p21 ^{CIP1} Compete For Binding To The Same Site On PCNA: A Potential Mechanism To Co-Ordinate DNA Replication And Repair" Oncogene, Vol. 14, pp. 2313-2321;
X	C10	Xiong, Yue et al. (1993) "p21 Is A Universal Inhibitor Of Cyclin Kinases" Nature Vol. 366, pp. 701-704;
X	C11	Zhang, Hui et al. (1994) "p21-Containing Cyclin Kinases Exist In Both Active And Inactive States" Genes & Development, Vol. 8, pp. 1750-1758.

Examiner	<i>David L. Lockett</i>	Date Considered
----------	-------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.